Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2008-03-18
2008-03-18
Anderson, Rebecca (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
Reexamination Certificate
active
07345086
ABSTRACT:
Methods, formulations, dosing regimes, and routes of administration for the treatment or prevention of arrhythmias, including the treatment or prevention of atrial fibrillation. In these methods, the disease or condition is treated or prevented by administering one or more ion channel modulating compounds to a subject, where the ion channel modulating compound or compounds produce specific plasma levels in the subject. The ion channel modulating compounds may be cycloalkylamine ether compounds, particularly cyclohexylamine ether compounds.
REFERENCES:
patent: 2954380 (1960-09-01), Shapiro et al.
patent: 3218328 (1965-11-01), Shapiro et al.
patent: 4145435 (1979-03-01), Szmuszkovicz
patent: 4179501 (1979-12-01), Szmuszkovicz
patent: 4598087 (1986-07-01), Horwell
patent: 4656182 (1987-04-01), Horwell
patent: 4663343 (1987-05-01), Horwell et al.
patent: 4855316 (1989-08-01), Horwell et al.
patent: 4880800 (1989-11-01), Wallis
patent: 4906655 (1990-03-01), Horwell et al.
patent: 5019588 (1991-05-01), Horwell et al.
patent: 5051428 (1991-09-01), Horwell et al.
patent: 5059620 (1991-10-01), Stout et al.
patent: 5492825 (1996-02-01), Jan et al.
patent: 5506257 (1996-04-01), MacLeod et al.
patent: 5637583 (1997-06-01), MacLeod et al.
patent: 5670335 (1997-09-01), Jan et al.
patent: 5728535 (1998-03-01), Lester et al.
patent: 5734021 (1998-03-01), Lester et al.
patent: 5750537 (1998-05-01), Nomura et al.
patent: 5817698 (1998-10-01), Brown et al.
patent: 5885984 (1999-03-01), MacLeod et al.
patent: 6174879 (2001-01-01), MacLeod et al.
patent: 6180632 (2001-01-01), Myers et al.
patent: 6210809 (2001-04-01), Okutomi et al.
patent: 6214809 (2001-04-01), Fermini et al.
patent: 6451819 (2002-09-01), Alanine et al.
patent: 6521619 (2003-02-01), Link et al.
patent: 6649603 (2003-11-01), Lum
patent: 2005/0020481 (2005-01-01), Bain et al.
patent: 2005/0026993 (2005-02-01), Beatch et al.
patent: 1234808 (1988-04-01), None
patent: 1235122 (1988-04-01), None
patent: 2004575 (1990-06-01), None
patent: 2058502 (1993-06-01), None
patent: 2172513 (1995-03-01), None
patent: 2240728 (1997-09-01), None
patent: 2008391 (1997-12-01), None
patent: 2289055 (1999-01-01), None
patent: 2268590 (2000-10-01), None
patent: 2132841 (2001-03-01), None
patent: 2 259 260 (1974-06-01), None
patent: 2 658 401 (1978-07-01), None
patent: 3 517 901 (1985-12-01), None
patent: 0147085 (1985-07-01), None
patent: 0222533 (1987-05-01), None
patent: 0147085 (1990-03-01), None
patent: 0372466 (1990-06-01), None
patent: 0380063 (1990-08-01), None
patent: 0380063 (1993-07-01), None
patent: 0552386 (1993-07-01), None
patent: 0720605 (2001-12-01), None
patent: 215963 (1998-02-01), None
patent: 02-270864 (1990-11-01), None
patent: WO 93/19056 (1993-09-01), None
patent: WO 94/07843 (1994-04-01), None
patent: WO 94/14435 (1994-07-01), None
patent: WO 95/08544 (1995-03-01), None
patent: WO 95/28155 (1995-10-01), None
patent: WO 96/18615 (1996-06-01), None
patent: WO 96/23894 (1996-08-01), None
patent: WO 97/32857 (1997-09-01), None
patent: WO 97/49680 (1997-12-01), None
patent: WO 99/02159 (1999-01-01), None
patent: WO 99/03468 (1999-01-01), None
patent: WO 99/11252 (1999-03-01), None
patent: WO 99/16431 (1999-04-01), None
patent: WO 99/50205 (1999-10-01), None
patent: WO 99/50225 (1999-10-01), None
patent: WO 00/47547 (2000-08-01), None
patent: WO 00/51981 (2000-09-01), None
patent: WO 01/96335 (2001-12-01), None
patent: WO 03/105756 (2003-12-01), None
patent: WO 2004/008103 (2004-01-01), None
patent: WO 2004/098525 (2004-11-01), None
patent: WO 2004/099137 (2004-11-01), None
Stevenson et al., Dec. 2, 2004, N. Engl. J. Med, 351; 23, 2437-2440.
Alzheimer's Disease Information Page [online], [retrieved on Oct. 3, 2006]. Retrieved from the internet, URL; <http://www.ninds.nih.gov/disorders/alzheimersdisease/alzheimersdisease.htm>.
Pratt et al., Oral vernakalant (RSD1235-SR) prevents recurrence of atrial fibrillation following cardioversion, poster presented at the 2007 Heart Rhythm Society Annual Meeting.
Abstract of DE 2 259 260, Derwent World Patents Index, Jun. 6, 1974.
Abstract of JP 02-270864, espacenet database, Nov. 5, 1990.
Adcock, J.J. et al., (2003) “RSD931, a novel anti-tussive agent acting on airway sensory nerves” Br J Pharm, 138:407-416.
Altria, Kevin D. et al., (2001) “Capillary Electrophoresis as a Routine Analytical Tool in Pharmaceutical Analysis” LCGC 19(9):972-985.
Amin et al., (1996) “RPR 101821, a New Potent Cholesterol-lowering Agent: Inhibition of Squalene Synthase and 7-Dehydrocholesterol Reductase”, Naunyn-Schmiedeberg's Arch Pharmacol 353:233-240.
Bain et al., (1997) “Better Antiarrythmics? Development of Antiarrhythmic Drugs Selective for Ischaemia-Dependent Arrhythmias”, Drug Development Research 42:198-210.
Barret, T. D. et al., (1996) “Glibenclamide Possesses Transient, Ischaemia Selective Class III Antiarrhythmic Actions But does not Prevent Ischaemic Arrhythmias” BPS Proceedings 116P.
Barrett, T. D. et al., (1997) “A model of myocardial ischemia for the simultaneous assessment of electrophysiological changes and arrhythmias in intact rabbits” J Pharmacol Toxicol Methods, 37:27-36.
Barrett, T.D. (2000) “Ischaemia selectivity confers efficacy for suppression of ischaemia-induced arrhythmias in rats” Eur J Pharm, 398:365-374.
Barrett, T.D. et al., (1996) “Atypical Dose Response curves for Antiarrhythmic Drugs” BPS Proceedings 115P.
Barrett, Terrance D. (1997) “Ischemia Selective Electrophysiological and antiarrhythmic actions of RSD1019 in ischemic cardiac tissue” J Mol Cell Cardiol, pp. 197.
Barrett, Terrance D. et al., (2000) “RSD 1019 suppresses ischaemia-induced monophasic action potential shortening and arrhythmias in anaesthetized rabbits” Br J Pharm,131.405-414.
Beatch et al., (2002) “RSD1235 Selectively Prolongs Atrial Refractoriness and Terminates AF in Dogs with Electrically Remodeled Atria”, Pharmacologist, 44(2) (Supplement I), A15: XIVthWorld Congress of Pharmacology: Meeting Abstracts.
Beatch, G. N. et al., “RSD1235, A Novel Atrial-Selective Antiarrhythmic Drug, Shows Rapid and Extensive Oral Absorption in Man” 12thInternational Congress on Cardiovascular Pharmacotherapy, May 7-10, 2003, Barcelona, Spain.
Beatch, G. N. et al., (2002) “Ventricular Fibrillation, and Uncontrolled Arrhythmia Seeking New Targets” Drug Develop Res 55: 45-52.
Beatch, G.N. et al., (1996) “Antihistamine-induced Ventricular Arrhythmias” BPS Proceedings 120P.
Beatch, G.N. et al., (1997) “Characterization of a Non-Human Primate Model of Drug-Induced Torsades De Pointes” Proc. West. Pharmacol. Soc., 40: 13-16.
Beatch, G.N. et al., (2002) “RSD1235 Selectively Prolongs Atrial Refractoriness and Terminates AF in Dogs with Electrically Remodeled Atria” PACE 24(Part II):698. Abstract 702.
Bian et al., (1998)“Effects of K-opiod receptor stimulation in the heart and the involvement of protein kinase C” Brit. J. Pharmacol. 124:600-606.
Billman, (2003) “RSD-1235 Cardiome”, Current Opinion Investigational Drugs 4(3):352-354.
Boiadjiev et al., (1996) “pH-Sensitive Exciton Chirality Chromophore..Solvatochromic Effects on Circular Dichroism Spectra”, Tetrahedron: Asymmetry 7(10):2825-2832.
Bowen et al., (1992)“Characterization of the enantiomers of cis-n-[2-(3,4-Dichlorophenyl)Ethyl]-N-Methyl-2-(1-Pyrrolidinyl)Cyclohexylamine (BD737 and BD738): Novel Compounds with High Affinity, Selectivity and Biological Efficacy at Sigma Receptors” J. Pharmacol. Exp. Ther. 262(1):32-40.
Cardiome Drug Effective for Heart Patients. Press Release Sep. 3, 2002, 3 pages.
Cardiome Pharma Completes Phase I Safety Study. New Release Transmitted By CNN Newswire, Jul. 30, 2001. 2 pages.
Cardiome Pharma Corp. Healthcare (Underweight) Company Report Dec. 12, 2002. 26 pages.
Cardiome Reports Dosing of First Patient in Pivotal Phase II Study. Press Release Jan. 17, 2002. 3 pages.
Beatch Gregory N.
Ezrin Alan M.
Anderson Rebecca
Cardiome Pharma Corp.
Seed IP Law Group PLLC
LandOfFree
Uses of ion channel modulating compounds does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Uses of ion channel modulating compounds, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Uses of ion channel modulating compounds will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2792310